Ovarian cancer is one of those. Ovarian cancer starts in the ovaries, which are two small glands located on either side of ...

Elahere shows consistent survival benefits in patients with folate receptor alpha-positive platinum-resistant ovarian cancer in the MIRASOL trial. Treatment with Elahere (mirvetuximab ...

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared ... resistant ovarian cancer (PROC) Data ...

Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endome | Genmab has shared the first data on ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

The final data analysis confirmed that mirvetuximab soravtansine-gynx (Elahere; AbbVie ... alpha-positive (FRα+) platinum-resistant ovarian cancer. The randomized, phase 3 MIRASOL trial included ...

Elahere is prescribed for certain types of cancer in adults. These include: fallopian tube cancer ovarian cancer peritoneal cancer An interaction occurs when one substance causes another substance ...

Elahere, which recorded sales of $479 million ... according to the company. Ovarian cancer affects more than 200,000 women in the U.S. each year, of which about 20,000 cases are classified as ...

"The significant improvements in survival, along with the well-characterized safety profile, reinforce ELAHERE as an emerging standard of care for difficult-to-treat ovarian cancer and warrants ...